Roche Venture Fund

Roche Venture Fund explicitly targets financial returns alongside strategic alignment. Its mandate is to invest in commercially successful innovative life science companies, rather than acquiring R&D assets on behalf of its parent. The fund operates with a profit-oriented motive, guided by long-term vision, but always with financial outcomes in mind.

The fund operates as an evergreen investment pool of CHF 750 million, funded directly from Roche Holding's corporate balance sheet. This permanent-capital structure removes the constraints of traditional fund cycles. It gives the investment team flexibility to hold positions indefinitely, without the pressure of returning capital to external LPs on a fixed timeline.

The fund focuses on three primary segments: pharmaceuticals, diagnostics, and digital health. Stage coverage is not explicitly bounded from public materials, but the mandate targets life science companies across the innovation lifecycle — from early ventures to more established commercial-stage businesses. Its portfolio contains more than 30 active companies.

Roche Venture Fund is the wholly owned corporate venture arm of Roche Holding AG, the global pharmaceutical and diagnostics company. The fund invests Roche's capital directly, and its team members are part of the broader Roche organization. This relationship provides portfolio companies with access to scientific expertise and long-term partnership opportunities within Roche's expansive healthcare ecosystem.

The fund takes active involvement within its portfolio companies, seeking to add operational value. While its website does not specify typical check sizes or leadership preferences, the fund's team of life-science investors is positioned to originate proprietary opportunities across its two offices in Basel and South San Francisco, frequently co-investing alongside traditional venture firms.